Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Weight increased13.15.01.006--
Dermatosis23.03.03.0170.000246%Not Available
Emotional distress19.04.02.008--Not Available
General physical health deterioration08.01.03.0180.000839%Not Available
Upper respiratory tract inflammation22.12.03.0340.000112%Not Available
Lower gastrointestinal haemorrhage07.12.03.011; 24.07.02.0300.000168%
Malignant neoplasm progression16.16.01.0050.000951%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000112%Not Available
Cytokine release syndrome10.02.01.0100.000112%
Lymphatic disorder01.09.01.003--Not Available
Epigastric discomfort07.01.02.004--Not Available
Nodule08.03.05.0020.000112%Not Available
Foetal death18.01.02.003; 08.04.01.0110.000168%
Haemorrhage24.07.01.0020.000616%Not Available
Varices oesophageal24.10.02.004; 09.01.06.009; 07.15.05.0010.000336%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.000168%Not Available
Nail pigmentation23.02.05.0070.000929%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.000951%Not Available
Angiopathy24.03.02.0070.000437%Not Available
Skin toxicity23.03.03.032; 12.03.01.020--Not Available
Drug resistance08.06.01.0050.000392%Not Available
Urine output13.13.03.003--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Recall phenomenon23.03.07.005; 12.02.06.001--
Neurological symptom17.02.05.010--Not Available
Breast disorder21.05.04.004--Not Available
Haematotoxicity01.05.01.007; 12.03.01.0250.000112%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation08.01.05.007; 10.02.01.0890.000112%Not Available
Malnutrition14.03.02.0040.000112%Not Available
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene